Unique in Europe, MATWIN (Maturation & Accelerating Translation With INdustry)
is an open-innovation platform that aims at developing translational research in oncology
and accelerating innovation transfer from bench to the bedside.

MATWIN’s main objective is to support innovative projects with high transfer potential by fostering early partnerships.

RESEARCH

Strenghten innovations’ transfer potential
in partnership with the national ecosystem
(canceropôles, TTOs, clusters…)

INDUSTRY

Mutualize a sourcing platform of
« shortlisted » early innovative projects

PATIENTS

Contribute to accelerate treatments
/ diagnostics outlooks



MATWIN IN FIGURES

2009 – 2021

0+
APPLICANTS
0
PROJECTS
interviewed by the Board
0+
START-UP
created
0+
PROJECTS
transferred
0+
PARTICIPANTS
for MEET2WIN

THE MATWIN PROGRAMME

The programme supports internationally competitive projects with strong industrial potential.
It maximizes their value for industry.

PROCESS

To understand project’s selection and qualification process…

LEARN MORE

APPLICATION

You have identified an innovation in oncology and you want to value it…

LEARN MORE

TECHNOLOGIES

Inventory of projects … that have reached the MATWIN Board audition since 2013

LEARN MORE

MEET2WIN 2022

7th EDITION I 12 & 13 MAY 2022 I BORDEAUX, FRANCE

MATWIN has organized the 7th edition of MEET2WIN in Bordeaux, France, on May 12nd and 13th, 2022,
European oncology partnering convention entirely dedicated to open innovation, collaborative research and technology transfer.

0+
PARTICIPANTS
0+
B2B meetings
LEARN MORE

OUR PARTNERS

INDUSTRIAL PARTNERS

13 pharma and diag companies
are actively partnering with MATWIN

LEARN MORE

INSTITUTIONAL PARTNERS

Unicancer, MATWIN’s main shareholder
is also highly involved in the programme

LEARN MORE

“ MATWIN, a useful player and invested in oncology. ”

Extract of the article “Zoom on Matwin” in the Laboratory Gazette of September 2017

NEWS


AGENDA


Stay informed about MATWIN’s activity by subscribing to our Newsletter


    OUR PARTNERS

    Logo unicancer